ProShares Ultra NASDAQ Biotechnology
33 hedge funds and large institutions have $21.7M invested in ProShares Ultra NASDAQ Biotechnology in 2017 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 8 increasing their positions, 12 reducing their positions, and 5 closing their positions.
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
3% more funds holding
Funds holding: 32 → 33 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2.4% less ownership
Funds ownership: 6.84% → 4.44% (-2.4%)
17% less capital invested
Capital invested by funds: $26.1M → $21.7M (-$4.39M)
33% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 12
57% less call options, than puts
Call options by funds: $10.4M | Put options by funds: $24.6M
Top Buyers
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AG
26
Advisor Group
Phoenix,
Arizona
| $7K | +$114 | +2 | +2% |
|
|
LTFS
27
Ladenburg Thalmann Financial Services
Miami,
Florida
| $6K | -$8.93K | -157 | -61% |
|
|
TRCT
28
Tower Research Capital (TRC)
New York
| $4K | -$1.54M | -26,996 | -100% |
|
|
MPWT
29
MassMutual Private Wealth & Trust
Windsor,
Connecticut
| $3.98K | +$3.7K | +65 | New |
|
|
VNA
30
Valley National Advisers
Bethlehem,
Pennsylvania
| $2K | +$1.42K | +25 | New |
|
|
YWP
31
YorkBridge Wealth Partners
New York
| $2K | +$1.71K | +30 | New |
|
32
Walleye Trading
New York
| $18 | +$10.1K | +177 | +145% |
|
33
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$1.35M | -23,786 | Closed |
|
|
BG
34
Bellevue Group
Kuesnacht,
Switzerland
| – | -$1.01M | -19,000 | Closed |
|
|
TSS
35
Two Sigma Securities
New York
| – | -$297K | -5,559 | Closed |
|
|
WSTAM
36
Wilbanks Smith & Thomas Asset Management
Norfolk,
Virginia
| – | -$231K | -4,330 | Closed |
|
|
CG
37
Cutler Group
San Francisco,
California
| – | -$5.69K | -100 | Closed |
|
BIB Hedge Fund Activity: Q3 2017 in Review
33 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in ProShares Ultra NASDAQ Biotechnology (BIB) for Q3 2017, worth a combined $21.7M — down 17% from $26.1M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new BIB positions and 5 closed out — a net gain of 3 holders — while 8 added to existing stakes and 12 trimmed.
The largest buyer was Geneos Wealth Management, adding an estimated $1.84M. The largest seller was RPG Investment Advisory, cutting an estimated $5.02M.
- 33 institutional investors held ProShares Ultra NASDAQ Biotechnology (BIB) as of Q3 2017, up from 32 in Q2 2017.
- Funds reported $21.7M of ProShares Ultra NASDAQ Biotechnology stock for Q3 2017, down 17% quarter-over-quarter.
- 8 funds opened new ProShares Ultra NASDAQ Biotechnology positions in Q3 2017 and 5 closed out, a net change of +3 holders.
- The largest ProShares Ultra NASDAQ Biotechnology buyer in Q3 2017 was Geneos Wealth Management, an estimated $1.84M added.
- The largest ProShares Ultra NASDAQ Biotechnology seller in Q3 2017 was RPG Investment Advisory, an estimated $5.02M sold.
Based on aggregated 13F filings for Q3 2017.